PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Journal of Alzheimer's Disease · 18.10.2024 · 101 (s1) · S579-S601
DOI: 10.3233/jad-240206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 18.10.2024. Verfasst von Poul F Høilund-Carlsen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Alzheimer Disease, Magnetic Resonance Imaging, Clinical Trials as Topic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 136 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
With the advent of PET imaging in 1976, 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET became the preferred method for in vivo investigation of cerebral processes, including regional hypometabolism in Alzheimer’s disease. With the emergence of amyloid-PET tracers, [11C]Pittsburgh Compound-B in 2004 and later [18F]florbetapir, [18F]florbetaben, and [18F]flumetamol, amyloid-PET has replaced FDG-PET in Alzheimer’s disease anti-amyloid clinical trial treatments to ensure “amyloid positivity” as an entry criterion, and to measure treatment-related decline in cerebral amyloid deposits. MRI has been used to rule out other brain diseases and screen for ‘amyloid-related imaging abnormalities’ (ARIAs) of two kinds, ARIA-E and ARIA-H, characterized by edema and micro-hemorrhage, respectively, and, to a lesser extent, to measure changes in cerebral volumes. While early immunotherapy trials of Alzheimer’s disease showed no clinical effects, newer monoclonal antibody trials reported decreases of 27% to 85% in the cerebral amyloid-PET signal, interpreted by the Food and Drug Administration as amyloid removal expected to result in a reduction in clinical decline. However, due to the lack of diagnostic specificity of amyloid-PET tracers, amyloid positivity cannot prevent the inclusion of non-Alzheimer’s patients and even healthy subjects in these clinical trials. Moreover, the “decreasing amyloid accumulation” assessed by amyloid-PET imaging has questionable quantitative value in the presence of treatment-related brain damage (ARIAs). Therefore, future Alzheimer’s clinical trials should disregard amyloid-PET imaging and focus instead on assessment of regional brain function by FDG-PET and MRI monitoring of ARIAs and brain volume loss in all trial patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA, USA.
Zitieren
APA
Høilund-Carlsen, P. F., Alavi, A., & Barrio, J. R. (2024). PET/CT/MRI in Clinical Trials of Alzheimer’s Disease. Journal of Alzheimer's Disease, 101(s1), S579-S601. https://doi.org/10.3233/jad-240206
Vancouver
Høilund-Carlsen PF, Alavi A, Barrio JR. PET/CT/MRI in Clinical Trials of Alzheimer’s Disease. Journal of Alzheimer's Disease. 2024;101(s1):S579-S601. doi:10.3233/jad-240206
BibTeX
@article{HilundCarlsen2024,
author = {Høilund-Carlsen, Poul F and Alavi, Abass and Barrio, Jorge R},
title = {PET/CT/MRI in Clinical Trials of Alzheimer’s Disease},
journal = {Journal of Alzheimer's Disease},
year = {2024},
volume = {101},
number = {s1},
pages = {S579--S601},
doi = {10.3233/jad-240206}
}
EUVIMED